Literature DB >> 3094572

Pharmacokinetics of the new benzodiazepine antagonist Ro 15-1788 in man following intravenous and oral administration.

G Roncari, W H Ziegler, T W Guentert.   

Abstract

During clinical pharmacology studies with the benzodiazepine antagonist Ro 15-1788 the pharmacokinetic characteristics of high intravenous doses (20 and 40 mg) and of an oral dose (200 mg) were examined in six healthy male volunteers. Ro 15-1788 was rapidly and extensively distributed in the body with an apparent volume of distribution Vss of 1.06 l kg-1. Elimination occurred rapidly by hepatic metabolism and the high plasma clearance of 1.14 l min-1 resulted in a short elimination half-life of less than 1 h. No difference in the disposition parameters calculated from the data after the 20 and 40 mg doses was observed reflecting a dose-proportionality in the areas under plasma concentration-time curves and unchanged distribution characteristics. Because the blood/plasma distribution coefficient is close to unity the disposition parameters obtained from plasma concentrations are similar to the corresponding parameters with reference to blood. Following oral administration of 200 mg the drug is rapidly absorbed. Peak levels were reached after 20-90 min and were close to or even higher than the values after the 40 mg intravenous dose at the same time point. Due to the high hepatic extraction ratio the fraction reaching the systemic circulation unchanged was reduced to approximately 16% during the absorption step.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3094572      PMCID: PMC1401170          DOI: 10.1111/j.1365-2125.1986.tb02912.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

1.  Influence of route of administration on drug availability.

Authors:  M Rowland
Journal:  J Pharm Sci       Date:  1972-01       Impact factor: 3.534

2.  Investigation in man of the efficacy of a benzodiazepine antagonist, Ro 15-1788.

Authors:  A Darragh; R Lambe; M Scully; I Brick; C O'Boyle; W W Downe
Journal:  Lancet       Date:  1981-07-04       Impact factor: 79.321

3.  Agonist and antagonist benzodiazepine receptor interaction in vitro.

Authors:  H Möhler; J G Richards
Journal:  Nature       Date:  1981-12-24       Impact factor: 49.962

4.  Tolerance of healthy volunteers to intravenous administration of the benzodiazepine antagonist Ro 15-1788.

Authors:  A Darragh; R Lambe; M Kenny; I Brick
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Noncompartmental determination of the steady-state volume of distribution.

Authors:  L Z Benet; R L Galeazzi
Journal:  J Pharm Sci       Date:  1979-08       Impact factor: 3.534

6.  Midazolam kinetics.

Authors:  H Allonen; G Ziegler; U Klotz
Journal:  Clin Pharmacol Ther       Date:  1981-11       Impact factor: 6.875

7.  [Pharmacokinetics of midazolam after i.v. administration (author's transl)].

Authors:  R Amrein; J P Cano; M Eckert; P Coassolo
Journal:  Arzneimittelforschung       Date:  1981

8.  Effect of the benzodiazepine antagonist Ro 15-1788 on flunitrazepam-induced sleep changes.

Authors:  J M Gaillard; R Blois
Journal:  Br J Clin Pharmacol       Date:  1983-05       Impact factor: 4.335

9.  Triazolam disposition.

Authors:  F S Eberts; Y Philopoulos; L M Reineke; R W Vliek
Journal:  Clin Pharmacol Ther       Date:  1981-01       Impact factor: 6.875

10.  Selective antagonists of benzodiazepines.

Authors:  W Hunkeler; H Möhler; L Pieri; P Polc; E P Bonetti; R Cumin; R Schaffner; W Haefely
Journal:  Nature       Date:  1981-04-09       Impact factor: 49.962

View more
  23 in total

Review 1.  Sedation for fibreoptic bronchoscopy.

Authors:  M P Shelley; P Wilson; J Norman
Journal:  Thorax       Date:  1989-10       Impact factor: 9.139

2.  Pharmacokinetics of flumazenil in fulminant hepatic failure.

Authors:  C C van der Rijt; R H Drost; S W Schalm; M Schramel
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  Pharmacology of drugs frequently used in ICUs: midazolam and flumazenil.

Authors:  R Amrein; W Hetzel
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

Review 4.  Flumazenil. A reappraisal of its pharmacological properties and therapeutic efficacy as a benzodiazepine antagonist.

Authors:  R N Brogden; K L Goa
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

Review 5.  Flumazenil in dentistry.

Authors:  C Rodrigo
Journal:  Anesth Prog       Date:  1995

Review 6.  A risk-benefit assessment of flumazenil in the management of benzodiazepine overdose.

Authors:  A A Weinbroum; R Flaishon; P Sorkine; O Szold; V Rudick
Journal:  Drug Saf       Date:  1997-09       Impact factor: 5.606

7.  Use of flumazenil in intoxicated patients with coma. A double-blind placebo-controlled study in ICU.

Authors:  R Ritz; M Zuber; S Elsasser; G Scollo-Lavizzari
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

8.  Flumazenil for the Treatment of Refractory Hypersomnolence: Clinical Experience with 153 Patients.

Authors:  Lynn Marie Trotti; Prabhjyot Saini; Catherine Koola; Vincent LaBarbera; Donald L Bliwise; David B Rye
Journal:  J Clin Sleep Med       Date:  2016-10-15       Impact factor: 4.062

Review 9.  Benzodiazepine antagonists. An update of their role in the emergency care of overdose patients.

Authors:  P J Kulka; P M Lauven
Journal:  Drug Saf       Date:  1992 Sep-Oct       Impact factor: 5.606

Review 10.  Benzodiazepine poisoning. Clinical and pharmacological considerations and treatment.

Authors:  P Gaudreault; J Guay; R L Thivierge; I Verdy
Journal:  Drug Saf       Date:  1991 Jul-Aug       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.